IBSA is a multinational Swiss pharmaceutical company founded in 1945.
IBSA’s corporate philosophy focuses on a strategy to optimise active ingredients while developing innovative pharmaceutical forms with increased efficacy and tolerability, able to maximise patient compliance and therapeutic results.
Testimony to this philosophy are core products such as Flector®, one of the first anti-inflammatory patches and market leader of its kind, Sinovial® (Rheumatology), Fostimon® (Human Reproduction) and Ialuset® (Dermatology).
IBSA is now an established name, not only in Switzerland but worldwide with new subsidiaries, highly specialised production facilities and joint-ventures abroad which have allowed the company to broaden the areas of activity resulting in ongoing expansion.
IBSA Farmaceutici Italia, the Italian based subsidiary boasts high level standards as a top quality manufacturer in the pharmaceutical, nutritional products and medical device fields.
Scientific knowledge, continued research, technological development and modern production processes, make IBSA one of the leading pharmaceutical companies in hyaluronic acid production including dermoaesthetic applications. IBSA distinguishes itself in this vast market because it controls the entire product life cycle, from the biofermentation raw material production to the finished product in pre-filled syringes.
HA-Derma are the UK distributors of IBSA Farmaceutici Italia’s range of hyaluronic acid based injectable products, including brands such as PROFHILO, ALIAXIN and VISCODERM.
Profhilo is first BDDE-free thermally stabilised hyaluronic acid for treating skin laxity.
© 2016 HA-DERMA Ltd. Website designed by www.compulink.london